21 Jan 2016 16:22
Taihua plc
("Taihua" or the "Company")
Renewal of Chinese Good Manufacturing Practice certificate
Delay to Production
The Company confirms today that its Chinese Good Manufacturing Practice ("GMP") certificate has now been granted and remains in force until 3 January 2021. Accordingly, the manufacturing of Homoharringtonine and Traditional Chinese Medicines can now resume.
However, the Company confirms that the issue of its Drug Production Permit ("DPP) which authorises the Company to sell its products within China has been delayed due to longer than expected SFDA procedures, accordingly there will be a temporary halt on the sales of Homoharringtonine and Traditional Chinese Medicines (but not Pacliataxel, which is sold outside China, or Forsythia, which is not covered by the DPP) until the DPP is issued.
The issue of the DPP is a priority for the directors of the Company, and it is anticipated that this will be issued before the end of March 2016. The impact on overall trading of the Group is unknown at this stage, and further updates will be provided in due course.
Enquiries:
Nicholas Lyth, Taihua plc 07769 906 686
Katy Mitchell, WH Ireland Limited +44 161 832 2174